Literature DB >> 1986602

A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women.

R J Urban1, J D Veldhuis.   

Abstract

We investigated serotoninergic regulation of prolactin release in estrogen-withdrawn postmenopausal women by using a serotonin reuptake inhibitor. Subjects underwent frequent blood sampling after placebo (basal) or fluoxetine administration. Mean 24-hour serum prolactin concentrations increased significantly in response to fluoxetine. Objective pulse analysis revealed no change in prolactin pulse frequency with serotoninergic stimulation, but maximal serum prolactin peak heights increased significantly. Multiple-parameter deconvolution disclosed no change in prolactin half-life, but a significant increase in the total mass of prolactin secreted per 24 hours during fluoxetine administration. Cosinor analysis of the prolactin time series showed a significant increase in the circadian amplitude and mean without any change in the time of maximal concentration during treatment with fluoxetine. We conclude that short-term activation of the serotoninergic system in the absence of substantial estradiol and opiatergic tone significantly increases the secretion of prolactin in postmenopausal women.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1986602     DOI: 10.1016/0002-9378(91)90645-8

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  13 in total

1.  Antipsychotic-induced euprolactinemic galactorrhea in an adolescent girl: a case report.

Authors:  Woo Jin Kwak; Ankit Patel; Fasiha Haq; Fatima Siddiqui; Mohammad Younis; Shakeel Raza; Radhika Gholkar
Journal:  Prim Care Companion CNS Disord       Date:  2012-02-02

2.  Antidepressant use and circulating prolactin levels.

Authors:  Katherine W Reeves; Olivia I Okereke; Jing Qian; Shelley S Tworoger; Megan S Rice; Susan E Hankinson
Journal:  Cancer Causes Control       Date:  2016-05-10       Impact factor: 2.506

3.  Use of antidepressants and NSAIDs in relation to mortality in long-term breast cancer survivors.

Authors:  Karen J Wernli; John M Hampton; Amy Trentham-Dietz; Polly A Newcomb
Journal:  Pharmacoepidemiol Drug Saf       Date:  2010-11-08       Impact factor: 2.890

Review 4.  A new logical insight and putative mechanism behind fluoxetine-induced amenorrhea, hyperprolactinemia and galactorrhea in a case series.

Authors:  Somnath Mondal; Indranil Saha; Saibal Das; Abhrajit Ganguly; Debasis Das; Santanu Kumar Tripathi
Journal:  Ther Adv Psychopharmacol       Date:  2013-12

Review 5.  Drugs and prolactin.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

Review 6.  Prolactin and breast cancer etiology: an epidemiologic perspective.

Authors:  Shelley S Tworoger; Susan E Hankinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

7.  Daily male exposure attenuates estrous cycle disruption by fluoxetine.

Authors:  Jhimly Sarkar; Cindy Hiegel; Navin Maswood; Lynda Uphouse
Journal:  Behav Brain Res       Date:  2007-12-23       Impact factor: 3.332

8.  Breast cancer recurrence risk in relation to antidepressant use after diagnosis.

Authors:  Jessica Chubak; Diana S M Buist; Denise M Boudreau; Mary Anne Rossing; Thomas Lumley; Noel S Weiss
Journal:  Breast Cancer Res Treat       Date:  2007-12-06       Impact factor: 4.872

9.  Antidepressant medications and change in mammographic density in postmenopausal women.

Authors:  Jessica Chubak; Erin J A Bowles; Mary Beth Terry; Amy Trentham-Dietz; Diana S M Buist
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-02-03       Impact factor: 4.254

10.  Pharmacological causes of hyperprolactinemia.

Authors:  Daria La Torre; Alberto Falorni
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.